BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Core Insights - BriaCell Therapeutics Corp. has been accepted into Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator 2025 Cohort program to expedite the clinical development of its personalized immunotherapy, Bria-OTS+, for various cancer types [1][2][3] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4] Collaboration Details - The partnership with MSK will provide BriaCell access to expertise and resources, including GMP manufacturing services and regulatory strategy support, to accelerate the development of Bria-OTS+ [2][3] - MSK has over 135 years of experience in cancer research and treatment, making it a valuable partner for BriaCell [2] Leadership Statements - Dr. William V. Williams, BriaCell's President and CEO, expressed honor in collaborating with MSK, highlighting the institution's expertise in cancer therapy development [3] - Dr. Miguel Lopez-Lago, Chief Scientific Officer, emphasized the potential of Bria-OTS+ to significantly improve cancer care for patients [4]